Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies

Critical Reviews in Clinical Laboratory Sciences

Volumn 51, Issue 4, 2014, Pages 200-231

  Ralla, Bernhard ^a   Stephan, Carsten ^a,b   Meller, Sebastian ^c   Dietrich, Dimo ^c   Kristiansen, Glen ^c   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Circulating cell free DNA; Kidney neoplasms; Methylation markers; MiRNAs; Prostatic neoplasms; RNA based markers; Testicular neoplasms; Urinary bladder neoplasms

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA FRAGMENT; MESSENGER RNA; NUCLEIC ACID; RNA; TUMOR MARKER;

BLADDER CANCER; BLOOD; BLOOD SAMPLING; BODY FLUID; CLINICAL PRACTICE; DNA ISOLATION; DNA METHYLATION; DNA STRAND; HUMAN; KIDNEY CARCINOMA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; META ANALYSIS (TOPIC); MICRORNA ISOLATION; MULTICENTER STUDY (TOPIC); MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA ISOLATION; TESTIS CANCER; URINALYSIS; URINE; PROGNOSIS; UROLOGIC NEOPLASMS;

HUMANS; NUCLEIC ACIDS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 84904703484     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2014.914888     Document Type: Review

References (330)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
2. Oosterwijk E, Rathmell WK, Junker K, et al. Basic research in kidney cancer. Eur Urol 2011;60:622-33
3. Huang J, Wang JK, Sun Y. Molecular pathology of prostate cancer revealed by next-generation sequencing: Opportunities for genome-based personalized therapy. Curr Opin Urol 2013;23: 189-93
4. Veltri RW, Makarov DV. Nucleic acid-based marker approaches to urologic cancers. Urol Oncol 2006;24:510-27
5. Choudhury AD, Eeles R, Freedland SJ, et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012;62: 577-87
6. Cheng L, Davison DD, Adams J, et al. Biomarkers in bladder cancer: Translational and clinical implications. Crit Rev Oncol Hematol 2014;89:73-111
7. Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview. J Cell Physiol 2013;228:1641-6
8. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61
9. Friedel R, Diederichs F, Lindena J. Release and extracellular turnover of cellular enzymes. In: Schmidt E, Schmidt FW, Trautschold I, Friedel R, eds. Advances in Clinical Enzymology. Basel: S. Karger AG, 1979:70-105
10. Peters DL, Pretorius PJ. Origin, translocation and destination of extracellular occurring DNA - A new paradigm in genetic behaviour. Clin Chim Acta 2011;412:806-11
11. Tzimagiorgis G, Michailidou EZ, Kritis A, et al. Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiol 2011;35:580-9
12. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-33
13. Rykova EY, Morozkin ES, Ponomaryova AA, et al. Cell-free and cell-bound circulating nucleic acid complexes: Mechanisms of generation, concentration and content. Expert Opin Biol Ther 2012;12:S141-53
14. Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet Mar 21;4:36. doi: 10.3389/fgene.2013.00036. eCollection 2013
15. Garcia-Olmo DC, Garcia-Olmo D. Biological role of cell-free nucleic acids in cancer: The theory of genometastasis. Crit Rev Oncog 2013;18:153-61
16. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - A critical appraisal of the literature. Clin Chim Acta 2010;411:1611-24
17. Pisetsky DS, Ullal AJ. The blood nucleome in the pathogenesis of SLE. Autoimmun Rev 2010;10:35-7
18. Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23:707-12
19. Beck J, Urnovitz HB, Riggert J, et al. Profile of the circulating DNA in apparently healthy individuals. Clin Chem 2009;55: 730-8
20. Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: Detection of tumor-Associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24
21. Puszyk WM, Crea F, Old RW. Unequal representation of different unique genomic DNA sequences in the cell-free plasma DNA of individual donors. Clin Biochem 2009;42:736-8
22. Swanton C. Plasma-derived tumor DNA analysis at whole-genome resolution. Clin Chem 2013;59:6-8
23. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000;906: 161-8
24. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61: 1659-65
25. Li CN, Hsu HL, Wu TL, et al. Cell-free DNA is released from tumor cells upon cell death: A study of tissue cultures of tumor cell lines. J Clin Lab Anal 2003;17:103-7
26. Suzuki N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008; 387:55-8
27. Garcia-Olmo DC, Samos J, Picazo MG, et al. Release of cell-free DNA into the bloodstream leads to high levels of non-Tumor plasma DNA during tumor progression in rats. Cancer Lett 2008; 272:133-40
28. Gahan PB, Anker P, Stroun M. Metabolic DNA as the origin of spontaneously released DNA?. Ann N Y Acad Sci 2008;1137:7-17
29. Gahan PB, Stroun M. The virtosome - A novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct 2010;28:529-38
30. Laktionov PP, Tamkovich SN, Rykova EY, et al. Cell-surfacebound nucleic acids: Free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients. Ann N Y Acad Sci 2004;1022:221-7
31. Peters DL, Pretorius PJ. Continuous adaptation through genetic communication - A putative role for cell-free DNA. Expert Opin Biol Ther 2012;12:S127-32
32. Kalra H, Simpson RJ, Ji H, et al. Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. PLoS Biol 2012;10:e1001450
33. Russo F, Di BS, Nigita G, et al. miRandola: Extracellular circulating microRNAs database. PLoS One 2012;7:e47786
34. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64: 218-24
35. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48: 1647-53
36. Tamkovich SN, Cherepanova AV, Kolesnikova EV, et al. Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci 2006;1075:191-6
37. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: The hypothesis of genometastasis. Ann N Y Acad Sci 2001; 945:265-75
38. Skvortsova TE, Vlassov VV, Laktionov PP. Binding and penetration of methylated DNA into primary and transformed human cells. Ann N Y Acad Sci 2008;1137:36-40
39. Lee TH, D'Asti E, Magnus N, et al. Microvesicles as mediators of intercellular communication in cancer - The emerging science of cellular debris'. Semin Immunopathol 2011;33:455-67
40. Finn NA, Searles CD. Using information theory to assess the communicative capacity of circulating microRNA. Biochem Biophys Res Commun 2013;440:1-7
41. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-52
42. Fuentes-Arderiu X. What is a biomarker?. It's time for a renewed definition. Clin Chem Lab Med 2013;51:1689-90
43. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50:298-301
44. Kirschner MB, van ZN, Reid G. Cell-free microRNAs: Potential biomarkers in need of standardized reporting. Front Genet 2013 Apr 19;4:56. doi: 10.3389/fgene.2013.00056. eCollection 2013
45. Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta 2009;404:100-4
46. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: Higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001;41:276-82
47. Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003;49:1028-9
48. Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sexmismatched bone marrow transplantation. Clin Chem 2002;48: 421-7
49. Chiu RW, Chan LY, Lam NY, et al. Quantitative analysis of circulating mitochondrial DNA in plasma. Clin Chem 2003;49: 719-26
50. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8
51. McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: Preanalytical and analytical challenges. Clin Chem 2011;57:833-40
52. Wang K, Yuan Y, Cho JH, et al. Comparing the microRNA spectrum between serum and plasma. PLoS One 2012;7:e41561
53. Kirschner MB, Edelman JJ, Kao SC, et al. The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 2013 May 24;4:94. doi:10.3389/fgene.2013.00094. eCollection 2013
54. Kim DJ, Linnstaedt S, Palma J, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn 2012;14:71-80
55. Sozzi G, Roz L, Conte D, et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005;97:1848-50
56. Gormally E, Hainaut P, Caboux E, et al. Amount of DNA in plasma and cancer risk: A prospective study. Int J Cancer 2004; 111:746-9
57. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6
58. El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta 2013;424: 222-30
59. Becker N, Lockwood CM. Pre-Analytical variables in miRNA analysis. Clin Biochem 2013;46:861-8
60. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: A critical analysis. J Urol 2013;189:422-9
61. Muller H, Brenner H. Urine markers as possible tools for prostate cancer screening: Review of performance characteristics and practicality. Clin Chem 2006;52:562-73
62. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95
63. Schmidt B, Weickmann S, Witt C, Fleischhacker M. Improved method for isolating cell-free DNA. Clin Chem 2005; 51:1561-3
64. Fong SL, Zhang JT, Lim CK, et al. Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem 2009;55:587-9
65. Chen W, Cai F, Zhang B, Zhong XY. Strategies of reducing input sample volume for extracting circulating cell-free nuclear DNA and mitochondrial DNA in plasma. Clin Chem Lab Med 2012;50: 261-5
66. Mouliere F, Robert B, Arnau PE, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011;6: E23418
67. Wang M, Block TM, Steel L, et al. Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004;50:211-3
68. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63: 3966-8
69. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58: 335-8
70. Burgos KL, Javaherian A, Bomprezzi R, et al. Identification of extracellular miRNA in human cerebrospinal fluid by nextgeneration sequencing. RNA 2013;19:712-22
71. McAlexander MA, Phillips MJ, Witwer KW. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front Genet 2013;4: 83
72. Redshaw N, Wilkes T, Whale A, et al. A comparison of miRNA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. Biotechniques 2013;54: 155-64
73. Sanders I, Holdenrieder S, Walgenbach-Brunagel G, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol 2012;19:1017-25
74. Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: Effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn 2013;15:827-34
75. Chun FK, Muller I, Lange I, et al. Circulating tumour-Associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006;98:544-8
76. Vitzthum F, Geiger G, Bisswanger H, et al. A quantitative fluorescence-based microplate assay for the determination of double-stranded DNA using SYBR Green I and a standard ultraviolet transilluminator gel imaging system. Anal Biochem 1999;276:59-64
77. Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-75
78. Ellinger J, Wittkamp V, Albers P, et al. Cell-free circulating DNA: Diagnostic value in patients with testicular germ cell cancer. J Urol 2009;181:363-71
79. Park JL, Kim HJ, Choi BY, et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett 2012;3: 921-6
80. Ramachandran K, Speer CG, Fiddy S, et al. Free circulating DNA as a biomarker of prostate cancer: Comparison of quantitation methods. Anticancer Res 2013;33:4521-9
81. Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004;205:173-80
82. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: Minimum information for publication of quantitative real-Time PCR experiments. Clin Chem 2009;55:611-22
83. van Der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin Biochem 2010;43:26-36
84. Wu TL, Zhang D, Chia JH, et al. Cell-free DNA: Measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002;321:77-87
85. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368-73
86. Pinheiro LB, Coleman VA, Hindson CM, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 2012;84:1003-11
87. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90
88. Huggett JF, Foy CA, Benes V, et al. The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin Chem 2013;59:892-902
89. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012 May 30;4(136):136ra68. doi: 10.1126/scitranslmed.3003726
90. Heitzer E, Ulz P, Belic J, et al. Tumor-Associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013 Apr 5;5(4):30. [Epub ahead of print].
91. Rivera CM, Ren B. Mapping human epigenomes. Cell 2013;155: 39-55
92. Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009;55: 1471-83
93. Kagan J, Srivastava S, Barker PE, et al. Towards clinical application of methylated DNA sequences as cancer biomarkers: A Joint NCI's EDRN and NIST Workshop on standards, methods, assays, reagents and tools. Cancer Res 2007;67:4545-9
94. Watson AK, Witwer KW. Do platform-specific factors explain microRNA profiling disparities?. Clin Chem 2012;58:472-4
95. Bustin SA, Benes V, Garson J, et al. The need for transparency and good practices in the qPCR literature. Nat Methods 2013;10: 1063-7
96. Cronin M, Ghosh K, Sistare F, et al. Universal RNA reference materials for gene expression. Clin Chem 2004;50:1464-71
97. Vaananen RM, Lilja H, Cronin A, et al. Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. Clin Biochem 2013;46:670-4
98. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010; Nov 26;9:306. doi: 10.1186/1476-4598-9- 306
99. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761-9
100. Ellinger J, Muller SC, Stadler TC, et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011;56:124-9
101. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: A review. Clin Biochem 2013. [Epub ahead of print]. doi:10.1016/j.clinbiochem.2013.10.023
102. Urquidi V, J Rosser C, Goodison S. Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis. Curr Med Chem 2012;19:3653-63
103. Huang X, Liang M, Dittmar R, Wang L. Extracellular microRNAs in urologic malignancies: Chances and challenges. Int J Mol Sci 2013;14:14785-99
104. Ma Y, Wang X, Jin H. Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci 2013;14: 10307-31
105. Bastian PJ, Palapattu GS, Yegnasubramanian S, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 2007;13:5361-7
106. Altimari A, Grigioni AD, Benedettini E, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008;129:756-62
107. Gordian E, Ramachandran K, Reis IM, et al. Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev 2010;19:1984-91
108. Delgado PO, Alves BC, Gehrke FS, et al. Characterization of cellfree circulating DNA in plasma in patients with prostate cancer. Tumour Biol 2013;34:983-6
109. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43
110. Ellinger J, Bastian PJ, Haan KI, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 2008; 122:138-43
111. Kwee S, Song MA, Cheng I, et al. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-Treated advanced prostate cancer. Clin Transl Sci 2012;5:65-70
112. Schwarzenbach H, Alix-Panabieres C, Muller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15:1032-8
113. Mehra N, Penning M, Maas J, et al. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 2007;13:421-6
114. Ellinger J, Muller SC, Wernert N, et al. Mitochondrial DNA in serum of patients with prostate cancer: A predictor of biochemical recurrence after prostatectomy. BJU Int 2008;102:628-32
115. Ellinger J, Muller DC, Muller SC, et al. Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies. Urol Oncol 2012;30:509-15
116. Casadio V, Calistri D, Salvi S, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: A pilot study. Biomed Res Int 2013;2013:270457. doi: 10.1155/2013/270457. Epub 2013 Feb 13
117. Barbieri CE, Bangma CH, Bjartell A, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64:567-76
118. Schwarzenbach H, Chun FK, Muller I, et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 2008;102:253-8
119. Muller I, Beeger C, Alix-Panabieres C, et al. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: Potential and technical improvements. Clin Chem 2008;54:688-96
120. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009;55:559-67
121. Hanley R, Rieger-Christ KM, Canes D, et al. DNA integrity assay: A plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res 2006;12:4569-74
122. Feng J, Gang F, Li X, et al. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostatespecific antigen. Int Urol Nephrol 2013;45:1023-8
123. Meiers I, Shanks JH, Bostwick DG. Glutathione S-Transferase pi (GSTP1) hypermethylation in prostate cancer: Review 2007. Pathology 2007;39:299-304
124. Wu T, Giovannucci E, Welge J, et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: A meta-Analysis. Br J Cancer 2011;105:65-73
125. Vener T, Derecho C, Baden J, et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008;54: 874-82
126. Roupret M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720-5
127. Payne SR, Serth J, Schostak M, et al. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009;69:1257-69
128. Baden J, Green G, Painter J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009; 182:1186-93
129. Shi J, Hu J, Zhou Q, et al. PEpiD: A prostate epigenetic database in mammals. PLoS One 2013;8:e64289
130. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75
131. Costa VL, Henrique R, Danielsen SA, et al. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 2011;6:1120-30
132. Baden J, Adams S, Astacio T, et al. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol 2011; 186:2101-6
133. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008;68:42-9
134. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: Progress towards clinical implementation. Expert Rev Mol Diagn 2012;12:473-87
135. Ahmed H, Cappello F, Rodolico V, Vasta GR. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: Development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2009; 2:146-56
136. Okegawa T, Nutahara K, Higashihara E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 2010;17:466-75
137. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008;122:952-6
138. Chao C, Chi M, Preciado M, Black MH. Methylation markers for prostate cancer prognosis: A systematic review. Cancer Causes Control 2013;24:1615-41
139. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15
140. Filella X, Foj L, Mila M, et al. PCA3 in the detection and management of early prostate cancer. Tumour Biol 2013;34: 1337-47
141. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-8
142. Deras IL, Aubin SM, Blase A, et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179: 1587-92
143. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011;21:225-9
144. Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-67
145. Hansen J, Auprich M, Ahyai SA, et al. Initial prostate biopsy: Development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013; 63:201-9
146. Perdona S, Cavadas V, Di Lorenzo G, et al. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: Head-To-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011;59:81-7
147. Tombal B, Andriole GL, de la Taille A, et al. Clinical judgment versus biomarker prostate cancer gene 3: Which is best when Determining the need for repeat prostate biopsy?. Urology 2013;81: 998-1004
148. Leyten GH, Wierenga EA, Sedelaar JP, et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci 2013;14:11347-55
149. Bradley LA, Palomaki GE, Gutman S, et al. Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013;190: 389-98
150. EGAPP Working Group. Recommendations from the EGAPP Working Group: Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?. Genet Med 2014;16:338-46
151. Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study. J Urol 2013;190:64-9
152. Stephan C, Jung K, Semjonow A, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59:280-8
153. Dijkstra S, Birker IL, Smit FP, et al. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014;191:1132-8
154. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8
155. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8
156. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8
157. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9
158. Cao DL, Ye DW, Zhang HL, et al. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011;71:700-10
159. Dimitriadis E, Kalogeropoulos T, Velaeti S, et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res 2013;33:191-7
160. Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013;19:2442-50
161. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013;31:566-71
162. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42
163. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970
164. Zielie PJ, Mobley JA, Ebb RG, et al. A novel diagnostic test for prostate cancer emerges from the determination of alphamethylacyl-coenzyme a racemase in prostatic secretions. J Urol 2004;172:1130-3
165. Zehentner BK, Secrist H, Zhang X, et al. Detection of alphamethylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. Mol Diagn Ther 2006;10: 397-403
166. Ouyang B, Bracken B, Burke B, et al. A duplex quantitative polymerase chain reaction assay based on quantification of alphamethylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009;181:2508-13
167. Jamaspishvili T, Kral M, Khomeriki I, et al. Quadriplex model enhances urine-based detection of prostate cancer. Prostate Cancer Prostatic Dis 2011;14:354-60
168. Rice KR, Chen Y, Ali A, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res 2010;16:1572-6
169. Rigau M, Morote J, Mir MC, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010;70: 1760-7
170. Rigau M, Ortega I, Mir MC, et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 2011;71:1730-45
171. Talesa VN, Antognelli C, Del BC, et al. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomark 2009;5:241-51
172. Liong ML, Lim CR, Yang H, et al. Blood-based biomarkers of aggressive prostate cancer. PLoS One 2012;7:e45802
173. Sabaliauskaite R, Jarmalaite S, Petroska D, et al. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes Chromosomes Cancer 2012;51:781-91
174. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720
175. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229
176. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxelbased chemotherapy. Prostate 2011;71:326-31
177. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16
178. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71:550-60
179. Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265.e9-16
180. Agaoglu FY, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011;32:583-8
181. Selth LA, Townley S, Gillis JL, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2011;131:652-61
182. Gonzales JC, Fink LM, Goodman OB Jr, et al. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9:39-45
183. Ahumada-Tamayo S. MicroRNA determination in urine for prostate cancer detection in Mexican Patients at the Hospital General "Dr. Manuel Gea Gonzalez. Rev Mex Urol 2011;71: 213-7
184. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 2012;72:1443-52
185. Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 2012;72:1469-77
186. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74
187. Nguyen HC, Xie W, Yang M, et al. Expression Differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013;73: 346-54
188. Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-Associated hypoxia. PLoS One 2013;8: E69239
189. Watahiki A, Macfarlane RJ, Gleave ME, et al. Plasma miRNAs as biomarkers to identify patients with castrationresistant metastatic prostate cancer. Int J Mol Sci 2013;14: 7757-70
190. Selth LA, Townley SL, Bert AG, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013;109:641-50
191. Srivastava A, Goldberger H, Dimtchev A, et al. MicroRNA profiling in prostate cancer - The diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8:e76994
192. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clin Transl Oncol 2012;14:803-11
193. Kelly BD, Miller N, Healy NA, et al. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int 2013;111:17-21
194. Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013;59: 132-7
195. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers?. Urol Oncol 2014;32:e1-9
196. Sapre N, Selth LA. Circulating microRNAs as biomarkers of prostate cancer: The state of play. Prostate Cancer 2013;2013: 539680. doi: 10.1155/2013/539680. Epub 2013 Mar 12
197. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 2013;108:1925-30
198. Zhang HL, Qin XJ, Cao DL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl 2013;15:231-5
199. Watahiki A, Wang Y, Morris J, et al. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011;6:e24950
200. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;22:S53-9
201. Xylinas E, Kluth LA, Rieken M, et al. Urine markers for detection and surveillance of bladder cancer. Urol Oncol 2014;32:222-9
202. Frantzi M, Makridakis M, Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 2012;22:390-6
203. Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60:484-92
204. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: Are we there yet?. Nat Rev Urol 2012;9:41-51
205. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008
206. Todenhofer T, Hennenlotter J, Witstruk M, et al. Influence of renal excretory function on the performance of urine based markers to detect bladder cancer. J Urol 2012;187:68-73
207. Zancan M, Franceschini R, Mimmo C, et al. Free DNA in urine: A new marker for bladder cancer?. Preliminary data. Int J Biol Markers 2005;20:134-6
208. Zancan M, Galdi F, Di TF, et al. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers 2009;24:147-55
209. Chang HW, Tsui KH, Shen LC, et al. Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers 2007;22:287-94
210. Casadio V, Calistri D, Tebaldi M, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. Urol Oncol 2013;31:1744-50
211. Ellinger J, Bastian PJ, Ellinger N, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity. Cancer Lett 2008;264:274-80
212. Bonberg N, Taeger D, Gawrych K, et al. Chromosomal instability and bladder cancer: The UroVysion(TM) test in the UroScreen study. BJU Int 2013;112:E372-82
213. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: A prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127:295-301
214. Larre S, Camparo P, Comperat E, et al. Diagnostic, staging, and grading of urothelial carcinomas from urine: Performance of BCA-1, a mini-Array comparative genomic hybridisation-based test. Eur Urol 2011;59:250-7
215. Szarvas T, Kovalszky I, Bedi K, et al. Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment. Oncol Rep 2007;18:405-9
216. van Rhijn BW, van Der Poel HG, van Der Kwast TH. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005;47:736-48
217. Zuiverloon TC, Beukers W, van Der Keur KA, et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: The European FP7 UROMOL project. J Urol 2013;189:1945-51
218. van Der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: Feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol 2009;55:659-67
219. Roupret M, Hupertan V, Yates DR, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008;101:1448-53
220. Frigerio S, Padberg BC, Strebel RT, et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer 2007;121:329-38
221. van Tilborg AA, Kompier LC, Lurkin I, et al. Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood. PLoS One 2012;7:e43345
222. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875-8
223. Kompier LC, Lurkin I, van Der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821
224. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010;101:250-8
225. Zuiverloon TC, Tjin SS, Busstra M, et al. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay. J Urol 2011;186:707-12
226. Otto W, Denzinger S, Bertz S, et al. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int J Cancer 2009;125:2205-8
227. Zuiverloon TC, van Der Aa MN, van Der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscleinvasive bladder cancer. Clin Cancer Res 2010;16:3011-8
228. van Kessel KE, Kompier LC, de Bekker-Grob EW, et al. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: A comparison of 3 strategies. J Urol 2013;189:1676-81
229. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6
230. Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013;73:1-6
231. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367-9
232. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-71
233. Junker K, van Oers JM, Zwarthoff EC, et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 2008;10:1-7
234. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70
235. Goessl C, Muller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002;41:668-76
236. Reinert T. Methylation markers for urine-based detection of bladder cancer: The next generation of urinary markers for diagnosis and surveillance of bladder cancer. Adv Urol 2012; 2012:503271. doi: 10.1155/2012/503271. Epub 2012 Jun 18
237. Vinci S, Giannarini G, Selli C, et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: A prospective, two-center validation study. Urol Oncol 2011;29:150-6
238. Reinert T, Borre M, Christiansen A, et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS One 2012;7:e46297
239. Scher MB, Elbaum MB, Mogilevkin Y, et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol 2012;188:2101-7
240. Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One 2010;5:e12334
241. Vaissiere T, Cuenin C, Paliwal A, et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics 2009;4: 221-30
242. Zhao Y, Guo S, Sun J, et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 2012;7:e35175
243. Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007;13:7296-304
244. Yegin Z, Gunes S, Buyukalpelli R. Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients. DNA Cell Biol 2013;32:386-92
245. Reinert T, Modin C, Castano FM, et al. Comprehensive genome methylation analysis in bladder cancer: Identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011;17:5582-92
246. Kandimalla R, van Tilborg AA, Kompier LC, et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol 2012;61:1245-56
247. Chihara Y, Kanai Y, Fujimoto H, et al. Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer 2013;13:275
248. Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-Time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010;58:96-104
249. Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010;16:5842-51
250. Monteiro-Reis S, Leca L, Almeida M, et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer 2014;50:226-33
251. Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in Detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 2010;28:597-602
252. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 2011;129:78-87
253. Kandimalla R, Masius R, Beukers W, et al. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin Cancer Res 2013;19:4760-9
254. Hoque MO, Begum S, Brait M, et al. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol 2008;179:743-7
255. Zuiverloon TC, Beukers W, van Der Keur KA, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int 2012;109:941-8
256. Garcia-Baquero R, Puerta P, Beltran M, et al. Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: A 2-center prospective study. J Urol 2013;190:723-30
257. Wolff EM, Chihara Y, Pan F, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010;70:8169-78
258. Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 2002;42:622-8
259. Ellinger J, El KN, Heukamp LC, et al. Hypermethylation of cellfree serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008;179:346-52
260. Dominguez G, Carballido J, Silva J, et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8: 980-5
261. Lin YL, Sun G, Liu XQ, et al. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res 2011;39:179-86
262. Hauser S, Kogej M, Fechner G, et al. Serum DNA hypermethylation in patients with bladder cancer: Results of a prospective multicenter study. Anticancer Res 2013;33:779-84
263. Mengual L, Burset M, Ars E, et al. Partially degraded RNA from bladder washing is a suitable sample for studying gene expression profiles in bladder cancer. Eur Urol 2006;50:1347-55
264. Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in Degraded RNA preparations from human tissue and cell samples. Clin Chem 2010;56:998-1006
265. Hanke M, Kausch I, Dahmen G, et al. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin Chem 2007;53:2070-7
266. Gelmini S, Quattrone S, Malentacchi F, et al. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: Preliminary experience. Clin Chem Lab Med 2007;45:862-6
267. Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008; 14:742-8
268. Eissa S, Zohny SF, Swellam M, et al. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem 2008;41:1335-41
269. Pu XY, Wang ZP, Chen YR, et al. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol 2008;134: 659-65
270. Guo B, Luo C, Xun C, et al. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-Time PCR. Exp Oncol 2009;31:43-7
271. Xia Y, Liu YL, Yang KH, Chen W. The diagnostic value of urinebased survivin mRNA test using reverse transcription-polymerase chain reaction for bladder cancer: A systematic review. Chin J Cancer 2010;29:441-6
272. Horstmann M, Bontrup H, Hennenlotter J, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 2010;28:399-404
273. Eissa S, Swellam M, Shehata H, et al. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 2010;183:493-8
274. Brems-Eskildsen AS, Zieger K, Toldbod H, et al. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 2010;10:646
275. Mengual L, Burset M, Ribal MJ, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res 2010;16:2624-33
276. Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011;117: 1197-209
277. Chen CH, Chen RJ. Prevalence of telomerase activity in human cancer. J Formos Med Assoc 2011;110:275-89
278. Bongiovanni L, Pirozzi F, Guidi F, et al. Bradeion (SEPT4) as a urinary marker of transitional cell bladder cancer: A real-Time polymerase chain reaction study of gene expression. J Urol 2012; 187:2223-7
279. Johnen G, Gawrych K, Bontrup H, et al. Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One 2012;7:e35363
280. O'Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012;188:741-7
281. Urquidi V, Goodison S, Cai Y, et al. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2149-58
282. Ku JH, Godoy G, Amiel GE, Lerner SP. Urine survivin as a diagnostic biomarker for bladder cancer: A systematic review. BJU Int 2012;110:630-6
283. Eissa S, Badr S, Elhamid SA, et al. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine. Dis Markers 2013;34: 57-62
284. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-73
285. Eissa S, Swellam M, Ali-Labib R, et al. Detection of telomerase in urine by 3 methods: Evaluation of diagnostic accuracy for bladder cancer. J Urol 2007;178:1068-72
286. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010;28:655-61
287. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: Correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011;102:522-9
288. Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 2012;15:1-5
289. Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 2012;10:106-13
290. Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012;107:123-8
291. Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 2012;41:1871-8
292. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012;180: 1808-15
293. Scheffer AR, Holdenrieder S, Kristiansen G, et al. Circulating microRNAs in serum: Novel biomarkers for patients with bladder cancer?. World J Urol 2014;32:353-8
294. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2012;31:1701-8
295. Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 2013;133:2631-41
296. Tolle A, Jung M, Rabenhorst S, et al. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep 2013;30:1949-56
297. Mall C, Rocke DM, Durbin-Johnson B, Weiss RH. Stability of miRNA in human urine supports its biomarker potential. Biomark Med 2013;7:623-31
298. Guancial EA, Bellmunt J, Yeh S, et al. The evolving understanding of microRNA in bladder cancer. Urol Oncol 2014;32:e31-40
299. Hauser S, Zahalka T, Ellinger J, et al. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. Anticancer Res 2010;30:2785-9
300. de Martino M, Klatte T, Haitel A, Marberger M. Serum cell-free DNA in renal cell carcinoma: A diagnostic and prognostic marker. Cancer 2012;118:82-90
301. Wan J, Zhu L, Jiang Z, Cheng K. Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma. Urol Int 2013;91:273-8
302. Feng G, Ye X, Fang F, et al. Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers 2013;34:105-11
303. Gang F, Guorong L, An Z, et al. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology 2010; 75:262-5
304. Purdue MP, Hofmann JN, Colt JS, et al. A case-control study of peripheral blood mitochondrial DNA copy number and risk of renal cell carcinoma. PLoS One 2012;7:e43149
305. Ramana J. RCDB: Renal Cancer Gene Database. BMC Res Notes 2012;5:246
306. Ashida S, Furihata M, Tanimura M, et al. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: Potential biomarkers for early diagnosis and postoperative metastatic status. J Urol 2003;169:2089-93
307. Battagli C, Uzzo RG, Dulaimi E, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695-9
308. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-7
309. Hauser S, Zahalka T, Fechner G, et al. Serum DNA hypermethylation in patients with kidney cancer: Results of a prospective study. Anticancer Res 2013;33:4651-6
310. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989-97
311. Gonzalgo ML, Eisenberger CF, Lee SM, et al. Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res 2002;8:1878-81
312. von Knobloch R, Hegele A, Brandt H, et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2002;98:889-94
313. Feng G, Li G, Gentil-Perret A, et al. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res 2008;28:321-6
314. Teratani T, Domoto T, Kuriki K, et al. Detection of transcript for brain-Type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology 2007;69:236-40
315. Zhao A, Li G, Peoc'h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013;94:115-20
316. Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012 Mar 22;10:55. doi: 10.1186/1479-5876-10-55
317. Hauser S, Wulfken LM, Holdenrieder S, et al. Analysis of serum microRNAs (miR-26a-2, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol 2012;36:391-4
318. Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One 2011;6:e25787
319. Zhai Q, Zhou L, Zhao C, et al. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun 2012;419:621-6
320. Zhao J, Lei T, Xu C, et al. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem Biophys Res Commun 2013;438:439-44
321. von Brandenstein M, Pandarakalam JJ, Kroon L, et al. MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 2012;180:1787-97
322. Ellinger J, Albers P, Perabo FG, et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol 2009;182:324-9
323. Ellinger J, Albers P, Muller SC, et al. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int 2009;104: 48-52
324. Kawakami T, Okamoto K, Ogawa O, Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 2004;363:40-2
325. Palmer RD, Murray MJ, Saini HK, et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res 2010;70:2911-23
326. Murray MJ, Halsall DJ, Hook CE, et al. Identification of microRNAs from the miR-371-373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol 2011;135:119-25
327. Dieckmann KP, Spiekermann M, Balks T, et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer 2012;107:1754-60
328. Gillis AJ, Rijlaarsdam MA, Eini R, et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: A proof of principle. Mol Oncol 2013;7: 1083-92
329. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLoS Med 2012;9: E1001216
330. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ 2002;324:539-41